SPY
—
QQQ
—
BTC/USD
—
DIA
—
GLD
—
TLT
—
US
Sign in
Register
My Account
Benzinga
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
The Chemours Co
CC
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$12.74
-0.17
-1.32%
Last update: Oct 16, 4:27 PM
$12.70
-0.21
-1.63%
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Dividends
Compare
Options
Stock Report
Privacy Manager
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
Chemours Financials
Chemours (CC) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Chemours Widens FY2026 Sales Guidance from $5.982B-$6.098B to $5.866B-$6.098B vs $6.044B Est
Chemours (NYSE:CC) widens FY2026 sales outlook from $5.982 billion-$6.098 billion to $5.866 billion-$6.098 billion vs $6.044 billion estimate.
Benzinga Newsdesk
PRO
Chemours Sees Q3 Sales $1.511B-$1.591B vs $1.601B Est
Chemours (NYSE:CC) sees Q3 sales of $1.511 billion-$1.591 billion vs $1.601 billion analyst estimate.
Benzinga Newsdesk
PRO
Chemours Q2 Adj. EPS $0.42, Inline, Sales $1.591B Miss $1.654B Estimate
Chemours (NYSE:CC) reported quarterly earnings of $0.42 per share which met the analyst consensus estimate. This is a 27.59 percent decrease over earnings of $0.58 per share from the same period last year. The company
Benzinga Newsdesk
PRO
Chemours Affirms FY2026 Sales Guidance of $5.982B-$6.098B vs $5.987B Est
Full Year 2026 Outlook The Company continues to expect 2026 Net Sales to grow in the range of 3% to 5% over 2025, with Adjusted EBITDA between $800 million and $900 million. This outlook is supported by higher TSS
Benzinga Newsdesk
PRO
Chemours Sees Q2 2026 Sales $1.588B-$1.657B vs $1.655B Est
Second Quarter 2026 Outlook In the second quarter, the Company anticipates consolidated Net Sales to increase in the range of 15% to 20% sequentially, driven by favorable seasonal trends, with consolidated Adjusted
Benzinga Newsdesk
PRO
Chemours Q1 Adj. EPS $0.05 Beats $(0.05) Estimate, Sales $1.381B Miss $1.387B Estimate
Benzinga Newsdesk
